Stockholm3 Test Validation in Men on Active Surveillance in Switzerland (CHAS3 Trial)
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexMale
AgeNot listed
SponsorInsel Gruppe AG, University Hospital Bern
About this trial
The CHAS3 trial studies whether the Stockholm3 blood test can reliably detect if prostate cancer becomes more aggressive in men who are being carefully monitored instead of treated right away (active surveillance). The goal is to see if this test can help doctors safely follow patients with fewer invasive procedures, such as repeated biopsies.
Eligibility criteria
Qualifiers
Adult Men ≥ 18 y. o.
Men with low-risk prostate cancer (D'Amico risk classification) currently undergoing Active Surveillance (AS)
First inclusion in Active Surveillance (AS) after 1st January 2022.
Scheduled for follow-up with systematic and/or Magnetic Resonance Imaging (MRI)-targeted (fusion) prostate biopsies - Prostate Magnetic Resonance Imaging (MRI) performed within the past three months available
Disqualifiers
- Prior prostate cancer treatment (surgery, radiation, chemotherapy, hormonal therapy).
Patient with intermediate- or high-risk prostate cancer
Urinary catheterization within the past 6-8 weeks
Contraindications to Magnetic Resonance Imaging (MRI) or biopsy
Trial design
Treatments tested in this trial
- Stockholm3
Treatment groups
350 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov